Musculoskeletal Disorders Drugs Market
Musculoskeletal Disorders Drugs Market Forecasts to 2030 - Global Analysis By Drug Type (Analgesics Corticosteroids and Other Drug Types), By Disorder Type (Fibromyalgia, Juvenile Idiopathic Arthritis, Osteoarthritis and Other Disorder Types), Treatment Type (Medication, Surgery and Other Treatment Types), Route of Administration, Distribution Channel, End User, By Geography
|
Years Covered |
2021-2030 |
|
Estimated Year Value (2023) |
US $88.6 BN |
|
Projected Year Value (2030) |
US $135.1 BN |
|
CAGR (2023-2030) |
6.2% |
|
Regions Covered |
North America, Europe, Asia Pacific, South America, and Middle East & Africa |
|
Countries Covered |
US, Canada, Mexico, Germany, UK, Italy, France, Spain, Japan, China, India, Australia, New Zealand, South Korea, Rest of Asia Pacific, South America, Argentina, Brazil, Chile, Middle East & Africa, Saudi Arabia, UAE, Qatar, and South Africa |
|
Largest Market |
North America |
|
Highest Growing Market |
Asia Pacific |
According to Stratistics MRC, the Global Musculoskeletal Disorders Drugs Market is accounted for $88.6 billion in 2023 and is expected to reach $135.1 billion by 2030 growing at a CAGR of 6.2% during the forecast period. Musculoskeletal disorder drugs are pharmaceuticals designed to treat conditions affecting the muscles, bones, joints, ligaments, and tendons. These disorders encompass a range of conditions, such as arthritis, osteoporosis, and musculoskeletal pain. The drugs aim to alleviate symptoms, manage inflammation, and modify disease progression, contributing to improved mobility and overall musculoskeletal health for individuals affected by these disorders.
According to WHO, 1.71 billion individuals globally suffer from musculoskeletal diseases, such as rheumatoid arthritis, osteoarthritis, low back pain, neck discomfort, fractures, and other injuries.
Market Dynamics:
Driver:
Rising prevalence of musculoskeletal disorders
The escalating prevalence of musculoskeletal disorders acts as a key driver in the musculoskeletal disorders drugs market. Factors such as aging populations, sedentary lifestyles, and an increase in chronic conditions contribute to a growing incidence of musculoskeletal issues like arthritis, osteoporosis, and musculoskeletal pain. This rising prevalence necessitates a corresponding surge in demand for effective pharmaceutical interventions. Consequently, pharmaceutical companies are prompted to invest in research and development, leading to the discovery and production of innovative drugs, thereby propelling the growth of the market.
Restraint:
Adverse side effects and high development costs
The occurrence of adverse effects associated with certain drugs can hinder patient compliance and acceptance. Additionally, the extensive research, development, and clinical trial processes contribute to elevated development costs. The financial burden of these costs may impede pharmaceutical companies from bringing novel and potentially groundbreaking musculoskeletal drugs to market promptly, limiting treatment options for patients impacting the overall growth and accessibility of effective therapies in the market.
Opportunity:
Surging demand for amyotrophic lateral sclerosis drugs
The increasing demand for amyotrophic lateral sclerosis drugs presents a notable opportunity in the musculoskeletal disorders drugs market. As awareness grows, there is a rising need for effective treatments to address this debilitating neurodegenerative disease. Pharmaceutical companies investing in amyotrophic lateral sclerosis drug development can tap into this expanding market, meeting the unmet medical needs of patients. Additionally, this contributes to the overall growth of the market.
Threat:
Insufficient availability of healthcare professionals
Musculoskeletal disorders often require specialized care, diagnosis, and treatment from healthcare professionals such as rheumatologists, orthopedic specialists, and physical therapists. The shortage of these professionals can result in delayed or inadequate patient care, hindering the proper identification and management of musculoskeletal disorders. This scarcity may lead to increased patient wait times, limited access to expert opinions, and challenges in implementing comprehensive treatment plans, affecting overall market growth.
Covid-19 Impact:
The COVID-19 pandemic has impacted the musculoskeletal disorder drug market in various ways. Lockdowns, disruptions in healthcare services, and economic uncertainties have influenced patient access to treatments. Delayed elective procedures and routine care appointments have affected drug consumption patterns. However, increased awareness of musculoskeletal health and the development of innovative telehealth solutions have partially mitigated these challenges during this period.
The juvenile idiopathic arthritis segment is expected to be the largest during the forecast period
The juvenile idiopathic arthritis segment is poised to dominate the musculoskeletal disorders drugs market during the forecast period due to the increasing incidence of juvenile idiopathic arthritis cases. Rising awareness, early diagnosis, and evolving treatment options contribute to the segment's growth. Pharmaceutical advancements, coupled with a focus on pediatric healthcare, drive research and development activities. Additionally, favorable regulatory support and initiatives for rare diseases further propel the prominence of the segment in the market.
The hospitals segment is expected to have the highest CAGR during the forecast period
The hospital segment is primed for substantial growth in the musculoskeletal disorders drug market. Hospitals serve as key healthcare centers for musculoskeletal disorder diagnosis, treatment, and management. The increasing prevalence of these disorders, coupled with a rising aging population, drives the demand for specialized medical care. Additionally, combined with the expanding healthcare infrastructure, the hospital segment is poised for significant growth.
Region with largest share:
Over the forecast period, North America is expected to dominate the Musculoskeletal Disorders Drugs market due to the high prevalence of musculoskeletal disorders, an aging population, and a well-established healthcare infrastructure. Additionally, increasing awareness, advanced diagnostic capabilities, and robust research and development activities contribute to the market's growth. Moreover, the presence of major pharmaceutical companies and favorable reimbursement policies further solidify North America's position.
Region with highest CAGR:
Over the forecast period, the Asia Pacific region is poised for substantial growth in the Musculoskeletal Disorders Drugs market due to increasing aging populations, lifestyle changes, and a rising prevalence of musculoskeletal disorders. Additionally, improving healthcare infrastructure, growing awareness, and rising disposable incomes contribute to increased accessibility to advanced medications. Moreover, pharmaceutical companies are likely to expand their presence in the region, fostering significant growth in the musculoskeletal disorders drugs market.
Key players in the market
Some of the key players in Musculoskeletal Disorders Drugs Market include Pfizer Inc., Novartis AG, Johnson & Johnson, Amgen Inc., AbbVie Inc., Roche Holding AG, Merck & Co., Inc., Eli Lilly and Company, Sanofi, GlaxoSmithKline plc, Regeneron Pharmaceuticals, Inc., Biogen Inc., AstraZeneca plc, Bristol Myers Squibb Company, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd. and Gilead Sciences, Inc.
Key Developments:
In Jun 2022, Pfizer came into collaboration with Sirana Pharma, a Germany-based developer of a biotechnology company. The collaboration involves investigating treatment for a rare bone disease, through leveraging Sirana’s microRNA targeting approach.
In March 2022, Pfizer completed the acquisition of Arena Pharmaceuticals, an American biopharmaceutical company. Through this acquisition, the company aimed to adjoin the amazing pipeline and experience of Arena Pharmaceuticals to Pfizer’s Immunology and swelling healing area, assisting further motive of advancement boost to change the lives of patients with the immuno-inflammatory illness.
Drug Types Covered:
• Analgesics
• Corticosteroids
• Disease-Modifying Antirheumatic Drugs (DMARDs)
• Other Drug Types
Disorder Types Covered:
• Fibromyalgia
• Juvenile Idiopathic Arthritis
• Osteoarthritis
• Psoriatic Arthritis
• Rheumatoid Arthritis
• Spondylarthritis
• Other Disorder Types
Treatment Types Covered:
• Medication
• Surgery
• Therapy
• Other Treatment Types
Route of Administrations Covered:
• Oral
• Parenteral
• Other Route of Administrations
Distribution Channels Covered:
• Hospital Pharmacy
• Online Providers
• Retail Pharmacy and Drug Stores
• Other Distribution Channels
End Users Covered:
• Diagnostic Centers
• Hospitals
• Rheumatologists
• Specialty Clinics
• Other End Users
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 End User Analysis
3.7 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Musculoskeletal Disorders Drugs Market, By Drug Type
5.1 Introduction
5.2 Analgesics
5.3 Corticosteroids
5.4 Disease-Modifying Antirheumatic Drugs (DMARDs)
5.5 Other Drug Types
6 Global Musculoskeletal Disorders Drugs Market, By Disorder Type
6.1 Introduction
6.2 Fibromyalgia
6.3 Juvenile Idiopathic Arthritis
6.4 Osteoarthritis
6.5 Psoriatic Arthritis
6.6 Rheumatoid Arthritis
6.7 Spondylarthritis
6.8 Other Disorder Types
7 Global Musculoskeletal Disorders Drugs Market, By Treatment Type
7.1 Introduction
7.2 Medication
7.3 Surgery
7.4 Therapy
7.5 Other Treatment Types
8 Global Musculoskeletal Disorders Drugs Market, By Route of Administration
8.1 Introduction
8.2 Oral
8.3 Parenteral
8.4 Other Route of Administrations
9 Global Musculoskeletal Disorders Drugs Market, By Distribution Channel
9.1 Introduction
9.2 Hospital Pharmacy
9.3 Online Providers
9.4 Retail Pharmacy and Drug Stores
9.5 Other Distribution Channels
10 Global Musculoskeletal Disorders Drugs Market, By End User
10.1 Introduction
10.2 Diagnostic Centers
10.3 Hospitals
10.4 Rheumatologists
10.5 Specialty Clinics
10.6 Other End Users
11 Global Musculoskeletal Disorders Drugs Market, By Geography
11.1 Introduction
11.2 North America
11.2.1 US
11.2.2 Canada
11.2.3 Mexico
11.3 Europe
11.3.1 Germany
11.3.2 UK
11.3.3 Italy
11.3.4 France
11.3.5 Spain
11.3.6 Rest of Europe
11.4 Asia Pacific
11.4.1 Japan
11.4.2 China
11.4.3 India
11.4.4 Australia
11.4.5 New Zealand
11.4.6 South Korea
11.4.7 Rest of Asia Pacific
11.5 South America
11.5.1 Argentina
11.5.2 Brazil
11.5.3 Chile
11.5.4 Rest of South America
11.6 Middle East & Africa
11.6.1 Saudi Arabia
11.6.2 UAE
11.6.3 Qatar
11.6.4 South Africa
11.6.5 Rest of Middle East & Africa
12 Key Developments
12.1 Agreements, Partnerships, Collaborations and Joint Ventures
12.2 Acquisitions & Mergers
12.3 New Product Launch
12.4 Expansions
12.5 Other Key Strategies
13 Company Profiling
13.1 Pfizer Inc.
13.2 Novartis AG
13.3 Johnson & Johnson
13.4 Amgen Inc.
13.5 AbbVie Inc.
13.6 Roche Holding AG
13.7 Merck & Co., Inc.
13.8 Eli Lilly and Company
13.9 Sanofi
13.10 GlaxoSmithKline plc
13.11 Regeneron Pharmaceuticals, Inc.
13.12 Biogen Inc.
13.13 AstraZeneca plc
13.14 Bristol Myers Squibb Company
13.15 Takeda Pharmaceutical Company Limited
13.16 F. Hoffmann-La Roche Ltd.
13.17 Gilead Sciences, Inc.
List of Tables
1 Global Musculoskeletal Disorders Drugs Market Outlook, By Region (2021-2030) ($MN)
2 Global Musculoskeletal Disorders Drugs Market Outlook, By Drug Type (2021-2030) ($MN)
3 Global Musculoskeletal Disorders Drugs Market Outlook, By Analgesics (2021-2030) ($MN)
4 Global Musculoskeletal Disorders Drugs Market Outlook, By Corticosteroids (2021-2030) ($MN)
5 Global Musculoskeletal Disorders Drugs Market Outlook, By Disease-Modifying Antirheumatic Drugs (DMARDs) (2021-2030) ($MN) 6 Global Musculoskeletal Disorders Drugs Market Outlook, By Other Drug Types (2021-2030) ($MN)
7 Global Musculoskeletal Disorders Drugs Market Outlook, By Disorder Type (2021-2030) ($MN)
8 Global Musculoskeletal Disorders Drugs Market Outlook, By Fibromyalgia (2021-2030) ($MN)
9 Global Musculoskeletal Disorders Drugs Market Outlook, By Juvenile Idiopathic Arthritis (2021-2030) ($MN)
10 Global Musculoskeletal Disorders Drugs Market Outlook, By Osteoarthritis (2021-2030) ($MN)
11 Global Musculoskeletal Disorders Drugs Market Outlook, By Psoriatic Arthritis (2021-2030) ($MN)
12 Global Musculoskeletal Disorders Drugs Market Outlook, By Rheumatoid Arthritis (2021-2030) ($MN)
13 Global Musculoskeletal Disorders Drugs Market Outlook, By Spondylarthritis (2021-2030) ($MN)
14 Global Musculoskeletal Disorders Drugs Market Outlook, By Other Disorder Types (2021-2030) ($MN)
15 Global Musculoskeletal Disorders Drugs Market Outlook, By Treatment Type (2021-2030) ($MN)
16 Global Musculoskeletal Disorders Drugs Market Outlook, By Medication (2021-2030) ($MN)
17 Global Musculoskeletal Disorders Drugs Market Outlook, By Surgery (2021-2030) ($MN)
18 Global Musculoskeletal Disorders Drugs Market Outlook, By Therapy (2021-2030) ($MN)
19 Global Musculoskeletal Disorders Drugs Market Outlook, By Other Treatment Types (2021-2030) ($MN)
20 Global Musculoskeletal Disorders Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
21 Global Musculoskeletal Disorders Drugs Market Outlook, By Oral (2021-2030) ($MN)
22 Global Musculoskeletal Disorders Drugs Market Outlook, By Parenteral (2021-2030) ($MN)
23 Global Musculoskeletal Disorders Drugs Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
24 Global Musculoskeletal Disorders Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
25 Global Musculoskeletal Disorders Drugs Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
26 Global Musculoskeletal Disorders Drugs Market Outlook, By Online Providers (2021-2030) ($MN)
27 Global Musculoskeletal Disorders Drugs Market Outlook, By Retail Pharmacy and Drug Stores (2021-2030) ($MN)
28 Global Musculoskeletal Disorders Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
29 Global Musculoskeletal Disorders Drugs Market Outlook, By End User (2021-2030) ($MN)
30 Global Musculoskeletal Disorders Drugs Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
31 Global Musculoskeletal Disorders Drugs Market Outlook, By Hospitals (2021-2030) ($MN)
32 Global Musculoskeletal Disorders Drugs Market Outlook, By Rheumatologists (2021-2030) ($MN)
33 Global Musculoskeletal Disorders Drugs Market Outlook, By Specialty Clinics (2021-2030) ($MN)
34 Global Musculoskeletal Disorders Drugs Market Outlook, By Other End Users (2021-2030) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.
